跳至主要内容
临床试验/ACTRN12609000595213
ACTRN12609000595213已完成未知

Quality of life assessment and disease free survival and overall survival in patients with mulitple myeloma after Tandem Autologous Stem Cell Transplantation (ASCT)

Clifford Craig Medical Research Trust0 个研究点目标入组 40 人开始时间: 2009年7月20日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • patients of either gender, 18 years and above who are able to give consent and have either: a confirmed diagnosis of multiple myeloma according to the World Health Organization (WHO) classification or patients who have been enrolled in our protocol with tandem stem cell transplantation

排除标准

  • Patient with renal impairment defined by an estimated creatinine clearance below < 15 ml/min based on the Cockcroft-Gault formula. (Creatinine clearance = (140-age) x ideal body weight (IBW in Kg) (x 0.85 if female) / (Serum creatinine. x 0.815).
  • Advanced liver disease (Child C with encephalopathy, ascites and a significantly elevated bilirubin, or pre-treatment coagulopathy).
  • Patients with Eastern Cooperative Oncology Group (ECOG) status>2

研究者

发起方
Clifford Craig Medical Research Trust

相似试验